Compare
Ionis Pharmaceuticals Inc vs Madrigal Pharmaceuticals, Inc. vs Harmony Biosciences Holdings, Inc. vs Prestige Consumer Healthcare Inc.
| Latest fiscal year | Ionis Pharmaceuticals Inc IONS | Madrigal Pharmaceuticals, Inc. MDGL | Harmony Biosciences Holdings, Inc. HRMY | Prestige Consumer Healthcare Inc. PBH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $943.71M | $958.40M | $868.45M | $1.09B |
| Revenue growth (YoY) | +33.8% | +432.1% | +21.5% | -4.3% |
| Gross margin | n/a | n/a | 77.2% | 54.7% |
| Operating margin | -40.4% | -31.3% | 24.0% | 28.4% |
| Net margin | -40.4% | -30.1% | 18.3% | 17.5% |
| Net income | -$381.39M | -$288.28M | $158.69M | $190.30M |
| EPS (Diluted) | -$2.38 | -$12.85 | $2.71 | $3.91 |
| Operating cash flow | -$268.58M | -$189.55M | $348.20M | $257.63M |
| Free cash flow | -$320.03M | -$190.02M | $347.89M | $246.45M |
| Cash & equivalents | $372.26M | $198.69M | $752.50M | $63.87M |
| Total assets | $3.52B | $1.26B | $1.27B | $3.49B |
| Total liabilities | $3.03B | $656.90M | $401.41M | $1.61B |
| Shareholders' equity | $489.09M | $602.69M | $870.22M | $1.89B |
| Return on year-end equity | -78.0% | -47.8% | 18.2% | 10.1% |
| Shares outstanding | 163.30M | 22.84M | 57.73M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Ionis Pharmaceuticals Inc | Madrigal Pharmaceuticals, Inc. | Harmony Biosciences Holdings, Inc. | Prestige Consumer Healthcare Inc. |
|---|---|---|---|---|
| Latest | $943.71M Ended 2025-12-31 | $958.40M Ended 2025-12-31 | $868.45M Ended 2025-12-31 | $1.09B Ended 2026-03-31 |
| 1 year earlier | $705.14M Ended 2024-12-31 | $180.13M Ended 2024-12-31 | $714.73M Ended 2024-12-31 | $1.14B Ended 2025-03-31 |
| 2 years earlier | $787.65M Ended 2023-12-31 | $0 Ended 2023-12-31 | $582.02M Ended 2023-12-31 | $1.13B Ended 2024-03-31 |
| 3 years earlier | $587.37M Ended 2022-12-31 | $0 Ended 2022-12-31 | $437.86M Ended 2022-12-31 | $1.13B Ended 2023-03-31 |
| 4 years earlier | $810.46M Ended 2021-12-31 | $0 Ended 2021-12-31 | $305.44M Ended 2021-12-31 | $1.09B Ended 2022-03-31 |